XML 94 R38.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Alcon subsidiaries | 12 Months Ended
--- | ---
Dec. 31, 2019
Disclosure Of Separate Financial Statements [Abstract] |
Alcon subsidiaries | Alcon subsidiaries The following table lists the Alcon legal entities with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements at and for the year ended December 31, 2019, respectively. The equity interest percentage shown in the table represents Alcon's share in voting rights in those entities. Unless otherwise stated, each entity has share capital consisting of equity held directly by the Company or another of its consolidated subsidiaries.
Country of organization/Entity name | Place of business | Equity interest |
Argentina |  |
Alcon Laboratorios Argentina S.A. | Buenos Aires | 100 | %
Australia |  |
Alcon Laboratories (Australia) Pty Ltd | Frenchs Forest, NSW | 100 | %
Austria |  |
Alcon Ophthalmika GmbH | Wein | 100 | %
Belgium |  |
Alcon Laboratories Belgium BVBA | Puurs | 100 | %
N.V. Alcon S.A. | Vilvoorde | 100 | %
Canada |  |
Alcon Canada Inc. | Mississauga, Ontario | 100 | %
Chile |  |
Alcon Laboratorios Chile Ltd. | Santiago de Chile | 100 | %
China |  |
Alcon (China) Ophthalmic Product Co., Ltd. | Beijing | 100 | %
Alcon Hong Kong Limited | Hong Kong | 100 | %
Colombia |  |
Laboratorios Alcon de Colombia S.A. | Santafé de Bogotá | 100 | %
Czech Republic |  |
Alcon Pharmaceuticals (Czech Republic) s.r.o. | Prague | 100 | %
Denmark |  |
Alcon Nordic A/S | Copenhagen | 100 | %
Dominican Republic |  |
Alcon Dominicana, SRL | Santo Domingo | 100 | %
Ecuador |  |
AlconLab Ecuador S.A. | Quito | 100 | %
France |  |
Laboratoires Alcon S.A.S. | Rueil-Malmaison | 100 | %
Germany |  |
Alcon Pharma GmbH | Freiburg im Breisgau | 100 | %
CIBA Vision GmbH | Grosswallstadt | 100 | %
WaveLight GmbH | Erlangen | 100 | %
Greece |  |
Alcon Laboratories Hellas- Single Member Commercial and Industrial S.A.C.I. | Maroussi, Athens | 100 | %
Hungary |  |
Alcon Hungary Pharmaceuticals Trading Limited Liability Company | Budapest | 100 | %
India |  |
Alcon Laboratories (India) Private Limited | Bangalore | 100 | %
Indonesia |  |
PT. CIBA Vision Batam | Batam | 100 | %
Ireland |  |
Alcon Laboratories Ireland Limited | Cork City | 100 | %
Israel |  |
Optonol Ltd. | Neve-Ilan | 100 | %
Country of organization/Entity name | Place of business | Equity interest |
Italy |  |
Alcon Italia S.p.A. | Milano | 100 | %
Japan |  |
Alcon Japan Ltd. | Tokyo | 100 | %
Malaysia |  |
Alcon Laboratories (Malaysia) Sdn. Bhd. | Petaling Jaya | 100 | %
CIBA Vision Johor Sdn. Bhd. | Kuala Lumpur | 100 | %
Mexico |  |
Alcon Laboratorios, S.A. de C.V. | Ciudad de Mexico | 100 | %
Morocco |  |
Alcon Maroc SARL D´Associé Unique | Casablanca | 100 | %
Netherlands |  |
Alcon Nederland B.V. | Arnhem | 100 | %
New Zealand |  |
Alcon Laboratories (New Zealand) Ltd. | Auckland | 100 | %
Panama |  |
Alcon Centroamerica S.A. | Panama City | 100 | %
Peru |  |
Alcon Pharmaceutical del Peru S.A. | Lima | 100 | %
Philippines |  |
Alcon Laboratories (Philippines), Inc. | Manila | 100 | %
Poland |  |
Alcon Polska Sp. z o.o. | Warszawa | 100 | %
Portugal |  |
Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda. | Porto Salvo | 100 | %
Puerto Rico |  |
Alcon (Puerto Rico), Inc. | Cataño, PR | 100 | %
Romania |  |
Alcon Romania S.R.L. | Bucharest | 100 | %
Russian Federation |  |
Alcon Farmacevtika LLC | Moscow | 100 | %
Singapore |  |
Alcon Pte Ltd | Singapore | 100 | %
Alcon Singapore Manufacturing Pte Ltd | Singapore | 100 | %
CIBA Vision Asian Manufacturing and Logistics Pte Ltd. | Singapore | 100 | %
South Africa |  |
Alcon Laboratories (South Africa) (Pty) Ltd. | Midrand | 100 | %
South Korea |  |
Alcon Korea Ltd. | Seoul | 100 | %
Spain |  |
Alcon Healthcare S.A. | Barcelona | 100 | %
Switzerland |  |
Alcon Inc. | Fribourg | 100 | %
Alcon Grieshaber AG | Schaffhausen | 100 | %
Alcon Management SA | Vernier | 100 | %
Alcon Pharmaceuticals Ltd. | Fribourg | 100 | %
Alcon Services AG | Fribourg | 100 | %
Alcon Switzerland SA | Risch | 100 | %
Thailand |  |
Alcon Laboratories (Thailand) Limited | Bangkok | 100 | %
Turkey |  |
Alcon Laboratuvarlari Ticaret A.S. | Istanbul | 100 | %
Country of organization/Entity name | Place of business | Equity interest |
Ukraine |  |
Alcon Ukraine LLC | Kiev | 100 | %
United Kingdom |  |
Alcon Eye Care UK Limited | Frimley/Camberley | 100 | %
United States of America |  |
Alcon Finance Corporation | Wilminton, DE | 100 | %
Alcon Laboratories, Inc. | Wilminton, DE | 100 | %
Alcon RefractiveHorizons, LLC | Fort Worth, TX | 100 | %
Alcon Research, LLC | Fort Worth, TX | 100 | %
Alcon Vision, LLC | Fort Worth, TX | 100 | %
CIBA Vision, LLC | Duluth, GA | 100 | %
WaveLight, Inc. | Sterling, VA | 100 | %
ClarVista Medical, Inc. | Aliso Viejo, CA | 100 | %
PowerVision, Inc. | Fort Worth, TX | 100 | %
Tear Film Innovations, Inc. | Fort Worth, TX | 100 | %
TrueVision Systems, Inc. | Fort Worth, TX | 100 | %
Alcon Lensx, Inc. | Fort Worth, TX | 100 | %
The list below shows the principal Novartis legal entities containing assets, liabilities and results of operations attributable to the Alcon business with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements.
Brazil(1)
Novartis Biociências S.A.
Mexico
Novartis Farmacéutica, S.A. de C.V.
(1) In accordance with the Separation and Distribution Agreement with Novartis, the separation from Novartis of the Alcon business in Brazil was delayed, and the Alcon business in Brazil remained in Novartis Biociências S.A. following the Spin-off. On February 3, 2020, the Alcon business in Brazil was transferred from Novartis Biociências S.A. to Alcon Brasil Cuidados com a Saúde Ltda. (“Alcon Brazil”), and on February 4, 2020, Alcon acquired from Novartis 100% of the ownership interests of Alcon Brazil, thereby completing the delayed transfer of the Alcon business in Brazil from Novartis to Alcon.

X
- Definition Disclosure Of Separate Financial Statements [Abstract] + References No definition available. + Details
Name: | alc_DisclosureOfSeparateFinancialStatementsAbstract
Namespace Prefix: | alc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B4 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration